VivoSim Labs (VIVS) Cash from Financing Activities (2010 - 2026)
VivoSim Labs (VIVS) posted quarterly Cash from Financing Activities of $2.9 million for Q1 2026, down 9.58% year-over-year from $3.2 million in Q1 2025, and up 2540.68% quarter-over-quarter from -$118000.0 in Q4 2025.
VivoSim Labs (VIVS) Cash from Financing Activities (2010 - 2026) Analysis & Trends
VivoSim Labs' Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $2.9 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 9.58% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $4.4 million (down 49.76% YoY), while the FY2026 annual figure was $4.4 million, down 49.76% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $2.9 million, up from -$118000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $6.2 million in Q2 2024, with the low at -$371000.0 in Q3 2024.
- The 4-year median for Cash from Financing Activities is $1.2 million (2023), against an average of $1.6 million.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities plunged 118.41% in 2024, then soared 1106.44% in 2025.
- VivoSim Labs' Cash from Financing Activities stood at $1.2 million in 2023, then slumped by 118.41% to -$216000.0 in 2024, then soared by 45.37% to -$118000.0 in 2025, then jumped by 2540.68% to $2.9 million in 2026.
- Business Quant data shows VIVS's Cash from Financing Activities at $2.9 million in Q1 2026, -$118000.0 in Q4 2025, and $1.7 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | -118,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -118,000.00 |
| Jun 30, 2026 | -118,000.00 |
| Mar 31, 2026 | 2.88 Mn |
| Mar 31, 2026 | 2.88 Mn |
| Dec 31, 2025 | -118,000.00 |
| Dec 31, 2025 | -118,000.00 |
| Jun 30, 2025 | 1.68 Mn |
| Jun 30, 2025 | 1.68 Mn |
| Mar 31, 2025 | 3.19 Mn |
| Mar 31, 2025 | 3.19 Mn |
| Dec 31, 2024 | -216,000.00 |
| Dec 31, 2024 | -216,000.00 |
| Sep 30, 2024 | -371,000.00 |
| Sep 30, 2024 | -371,000.00 |
| Jun 30, 2024 | 6.25 Mn |
| Jun 30, 2024 | 6.25 Mn |
| Mar 31, 2024 | 264,000.00 |
| Mar 31, 2024 | 264,000.00 |
| Dec 31, 2023 | 1.17 Mn |
| Dec 31, 2023 | 1.17 Mn |